- Sales amounted to SEK 187 (162) million, corresponding to an increase of 15 percent in SEK. Sales growth was 16 percent in local currency.
- Operating income before depreciation and amortization (EBITDA) amounted to SEK 62 (54) million, corresponding to a margin of 33 (33) percent. Operating income included one-time expenses of SEK 5 million related to the planned consolidation of the time-lapse business. Adjusted for this, the margin amounted to 36 percent.
- Launch of a new range of aspiration needles for oocyte retrieval.
- Net income amounted to SEK 39 (35) million, which gave earnings per share of SEK 1.77 (1.61).
Gothenburg, April 26, 2016
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 26, 2015 at 08:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.